Merck to stop lung condition drug study early due to strong efficacy data
Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...
STAT9d
Merck’s earnings miss focused attention on Gardasil. The real issue is Keytruda
the best-selling drug in the world, to decline in the coming years? And can they trust Merck’s guidance on that decline? The problems with Gardasil relate entirely to sales of the vaccine in ...
Yahoo Finance12d
Merck Halts Second PAH Drug Study Early on Strong Efficacy Results
Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension (PAH) drug, Winrevair (sotatercept), for a more advanced version of ...
Merck KGaA in Talks to Buy SpringWorks Therapeutics
Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare ...
Merck In Talks to Buy Cancer Drugmaker Springworks
After a slow 2024, dealmaking in the U.S. healthcare sector is picking up. Springworks has a market value of $3 billion.
Germany’s Merck in Talks to Buy SpringWorks Therapeutics
Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...
BioPharma Dive1d
Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK
The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority ...
Merck & Company Hold Rating: Promising Drug Developments Amid Uncertain Financial Outlook
Morgan Stanley analyst Terence Flynn has maintained their neutral stance on MRK stock, giving a Hold rating yesterday.Invest with Confidence: ...
FiercePharma12d
Merck vaccine, Daiichi ADC win approval recommendations in busy week at EU's drug regulator
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...